A case–control study shows oxidized LDL (oxLDL)-induced activation and maturation of DC are stronger in patients with SLE than in healthy controls, and this effect can be suppressed by the inhibition of PCSK9, indicating that PCSK9 may be involved in the progression of SLE by affecting inflammatory and immune-related pathways [10]. The gene discussed is PCSK9; the disease is systemic lupus erythematosus.